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doi:10.1Objective: Transcatheter occlusion of secundum atrial septal defects is a safe and effective alternative to tradi-
tional surgical closure; however, it is associated with serious occasional complications and inapplicable to more
than 20% of atrial septal defects. In 2000, transthoracic occlusion was pioneered at Xijing Hospital as a novel
method of atrial septal defect closure. The purpose of this study is to report the early and mid-term results of the
transthoracic occlusion procedure and to evaluate its safety and efficacy.
Methods: From April 2000 to April 2006, 268 patients with atrial septal defects were classified into 2 groups:
group A (unsuitable for transcatheter occlusion, n ¼ 126) and group B (n ¼ 142). The transthoracic occlusion
method used transesophageal echocardiographic-guided atrial septal defects occluder deployment via a right
minithoracotomy without cardiopulmonary bypass or fluoroscopy.
Results: Device implantation was successful in 265 patients (98.9%), including 9 elliptical devices in group A.
The average size of circular occluders in group Awas 38.2 4.2 mm, which was larger than in group B (24.0
4.5 mm) (P<.001). The average procedure time was 37.2 9.2 minutes, the average intracardiac manipulation
time was 5.8  3.0 minutes, and the average inpatient stay was 3.2  0.8 days. Twenty-five complications
(9.3%) occurred in patients during the follow-up period. No large residual shunting, device embolization, or
other severe complications resulted from transthoracic occlusion.
Conclusions: Transthoracic occlusion is a new safe and effective method for atrial septal defect treatment, even
for patients with partial atrial septal defects unsuitable for transcatheter occlusion. This hybrid method broadens
the indications of atrial septal defect treatment with device occlusion. (J Thorac Cardiovasc Surg 2011;142:113-9)C
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DThe atrial septal defect (ASD) is one of the most common
congenital heart defects, occurring in approximately 1 in
1500 live births.1 Transcatheter occlusion (TCO) of ASD
is a safe, effective alternative to traditional surgical closure,2
with many favorable merits, including superior cosmetic re-
sults, less trauma, avoidance of cardiopulmonary bypass
(CPB), and a shorter hospital stay.3,4 However, TCO has
still been associated with occasional complications, such
as device embolization, residual shunt, vessel injury, and
perforation of the heart.5-7 Furthermore, not all ASD
lesions are treatable by transcatheter closure because of
strict inclusion criteria, and as a result, 20% to 30% of
patients must undergo CPB operation for ASD repair.4,8e Institute of Cardiovascular Surgerya and Department of Ultrasonography,b
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The Journal of Thoracic and CaOn April 13, 2000, the Institute of Cardiovascular Sur-
gery successfully performed ASD occlusion via a novel
transthoracic occlusion (TTO) implantation method, the
first of its kind in the world.9,10 By using transesophageal
echocardiography (TEE) guidance, this novel method is
capable of ASD occlusion via a small 2- to 3-cm incision,
without CPB or fluoroscopy. Since the creation of TTO of
ASD, with continual improvement of the technique, the
procedure has been applied in many institutions in China,
which have reported its advantages of safety and
efficacy.11,12 TTO is particularly advantageous in its
suitability for ASD lesions incompatible for TCO repair.
From April 2000 to April 2006, we performed TTO of
ASD in 268 patients, including 126 patients deemed
unsuitable for TCO treatment. This retrospective study,
with the early and mid-term follow-up results, analyzes
the safety and efficacy of TTO for isolated secundum
ASDs, especially for patients unfit for TCO.METHODS AND MATERIALS
Patient Population
From April 2000 to April 2006, 268 patients underwent transthoracic
closure of ASD. ASD was diagnosed in these patients by transthoracic
echocardiography performed by 2 experienced echocardiographers
(board-certified ultrasonography attending physicians) whowere consulted
by senior interventional cardiologists and cardiovascular surgeons experi-
enced in TTO. The ASD closure method was chosen by specialistrdiovascular Surgery c Volume 142, Number 1 113
Abbreviations and Acronyms
ASD ¼ atrial septal defect
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
TCO ¼ transcatheter occlusion
TEE ¼ transesophageal echocardiography
TTO ¼ transthoracic occlusion
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Drecommendation and the patient or guardian. Table 1 lists the inclusion cri-
teria for patients undergoing TTO and TCO. All patients undergoing TTO
were divided into 2 groups (A and B). Group A consisted of 126 patients:
120 patients who were deemed unsuitable for TCO repair by Table 1 crite-
ria and 6 patients who previously failed ASD closure by TCO attempt.
Group B consisted of 142 patients who satisfied the TCO repair criteria
but chose TTO repair. All patients were fully informed about TTO and
gave consent before the operation. The ethics committee of our hospital
approved the use of the TTO technique of ASD closure.
Operation Preparation
TTO was performed in the cardiothoracic operation room, where CPB
was readily available if necessary. Each patient underwent general anesthe-
sia with tracheal intubation in the supine position.
Transesophageal Echocardiography
TEEwas performedby experienced echocardiographers (board-certified
ultrasonography attending physicians) who confirmed the anatomic details
of each individual ASD case, determined the size and type of occlusion de-
vice needed, and verified the feasibility of TTO success. TEE garnered an-
atomic details, such as the maximum ASD longitudinal and horizontal
diameters, as well as the rim measurements from the defect margins to
important surrounding structures, such as the aortic root, coronary sinus,
atrioventricular valves, right pulmonary vein, superior vena cava, and infe-
rior vena cava. TEEalso assessed the floppiness of the interatrial septumand
the hardness of the surroundingASDrim tissue. Floppy interatrial septumor
soft ASD rim tissues require larger occluder devices to ensure a positive seal
and prevent shunt or leak. If the TEE identifiedASDmorphology dissimilar
from earlier preoperative transthoracic echocardiography and the patient no
longer fit TTO inclusion criteria as a result, the patientwould be prepared for
conventional open surgical intervention directly.
Devices and Occluders Selection
The simple delivery system consisted of a straight sheath and a cable
(KeWeiMedical Apparatus Co, Dongguan, China). Occluders from 2man-
ufacturers (APAC Scientific International Co, and Ke Wei Medical Appa-
ratus Co, Beijing, China) were used in our study. Both circular and
elliptical occluders (both double-disc) are available and similar to the Am-
platzer (AGA Medical Corp, Plymouth, Minn) septal occluder in design,
but they possess harder rims. A sizing balloon is unnecessary in TTO.
Proper occluder size is selected by adding 3 to 5 mm to the maximum
ASD diameter for a round-type ASD. For elliptical or large size ASDs,
a special elliptical occluder 4 mm larger than the maximum longitudinal
diameter is chosen. For rims diagnosed as being soft by TEE, an additional
2 mm was added to the chosen occluder size.
Implantation Technique
The supine patient was padded below the right shoulder and lower right
lumbar region with approximately 20-cm foam support. An incision ap-
proximately 2.0 to 3.0 cm was made in the right anterior fourth intercostal114 The Journal of Thoracic and Cardiovascular Surgspace, immediately laterally to the sternum. Sufficient exposure
was achieved with a mini-retractor. Heparin drip was then initiated at
1.0 mg/kg, and bedside testing of the patient’s blood was performed.
We ensured that the patient had an activated clotting time more than 200
seconds before device deployment. The pericardium was incised approxi-
mately 2 cm superior to the phrenic nerve and suspended with four 1-0 silk
sutures. Two parallel purse-string sutures of 3-0 or 4-0 Prolene (Ethicon,
Inc, Somerville, NJ) were placed on the right atrium. The selected occlu-
sion device was fixed into a straight sheath. A right atrial puncture was
made within the purse-string sutures, and the sheath was inserted. Under
TEE guidance, the sheath was advanced through the defect into the left
atrium. By advancing the delivery cable, the atrial disc was extruded and
adjusted to be parallel with the atrial septum. Both sheath and cable were
withdrawn until the occlusion disc joined the atrial septum. ASD occlusion
was confirmed by the disappearance of any left to right shunt detectable by
TEE. Before the device was released, the occlusion disc’s stability was
confirmed via a repeated push-pull maneuver. If TEE revealed any obvious
residual shunting, an unstable occlusion disc, or a disc encroaching on
adjacent structures, the devicewas redeployed and repositioned. If satisfac-
tory ASD occlusion was achieved, the sheath was withdrawn, and the
purse-string sutures were tied. The initial thoracic incisionwas closed with-
out drainage tube placement (Figure 1, A–H).
Perioperative Evaluation and Follow-up
All patients were transferred to the intensive care unit (ICU) for recov-
ery and monitoring postoperatively. All patients underwent baseline clini-
cal examination, electrocardiography, chest radiography, and transthoracic
echocardiography before surgery; as inpatients postoperatively before
discharge; at 1, 3, and 12 months postdischarge; and annually thereafter.
Anti-aggregation therapy consisted of heparin (administered during the
first 24 hours postoperatively) and aspirin (3–4 mg/kg/d, continued for
6 months postoperatively).
Statistical Analysis
For nominal values, data are expressed as a frequency or percentage;
for continuous variables, data are expressed as mean values and standard
deviations. Ranges are expressed when data were not normally distributed.
Differences between groups were compared using unpaired, 2-sided Stu-
dent t tests for continuous variables. The chi-square test or Fisher’s exact
test was used for categoric variables. Data were analyzed using SPSS
software (Version 13.0; SPSS Inc, Chicago, Ill).
RESULTS
General Characteristics
There was no difference in gender, age, or body weight
distribution between groups A and B (Table 2). The average
diameter of the ASD in all patients was 26.9  6.1 mm
(5–44 mm), with group A having a significantly larger
ASD diameter (33.6  4.5; range, 12–44 mm; P<.001). In
group A, the ASDs of 89 patients (70.6%) were larger than
30 mm (P< .001, compared with group B). Most of the
ASDs in groupBwere the central type. GroupAhad a greater
heterogeneousmix ofASD type andmore superior vena cava,
inferior vena cava, and blending type than group B (P<.01).
Analysis of the Transthoracic Occlusion Group
Unsuitable for Transcatheter Occlusion
A total of 126 patients were deemed unsuitable for TCO
treatment by inclusion criteria. These patients (assigned to
group A) satisfied TTO inclusion criteria and underwentery c July 2011
TABLE 1. Inclusion criteria of patients selected for transcatheter
occlusion and transthoracic occlusion
Inclusion criteria
of TCO
Inclusion criteria
of TTO
Age 3 y 2 y
Clinical
manifestation
Symptomatic or
signs of right
ventricular
volume overload
Same as TCO
Morphology of ASD
Size 36 mm in adults
and smaller in young
children according
to femoral vessel
No limitation
Type Mainly central No limitation
Rim measurements Generally no more
than 2 rims
 5 mm
in 1 patient
Inferior-posterior rim
(toward IVC)
5 mm 0
Superior-posterior rim
(toward SVC)
5 mm 2 mm
Posterior rim
(toward PV)
5 mm 2 mm
Inferior rim
(toward AV)
5 mm 2 mm
Anterior-superior rim
(toward AR)
2 mm 0
Coronary sinus rim 5 mm 5 mm
TCO, Transcatheter occlusion; TTO, transthoracic occlusion; ASD, atrial septal de-
fect; IVC, inferior vena cava; SVC, superior vena cava; PV, pulmonary vein; AV, atrio-
ventricular valve; AR, aortic root.
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DTTO. More than half of these 126 patients (57.1%, 72/126)
were unsuitable for TCO because of ASD lesions with di-
minutive rims, especially inferiorly (48.6%, 35/72). In
group A, 27.8% (35/126) did not receive TCO because of
oversized ASD lesions (of these, 24 patients had ASD
lesions>36 mm, the absolute upper limit cutoff, and the re-
maining 11 patients had oversized ASD lesions relative to
the circumference of their femoral vessels). In group A,
5.6% (7/126) were unsuitable for TCO because of intera-
trial septal floppiness or rim softness, including 3 patients
who had failed previous TCO attempts. Peripheral vascular
diseases (2.4%, 3/126), allergy to contrast agent (0.8%,
1/126), and age less than 3 years (6.3%, 8/126) were the
factors accounting for TCO unsuitability in the remaining
patients in group A (Table 3).
Intraoperative Results
Successful implantation of the ASD occluder device was
achieved in 265 patients (98.9%), including 15 patients
with double ASDs occluded with a single device through
the larger defect. Correct placement of the device without
redeployment was achieved in 249 patients (92.9%). TTOThe Journal of Thoracic and Cafailed in 3 patients who immediately underwent cardiac by-
pass surgery. In 1 patient (group A), the ASD occluder was
displaced into the right ventricular outlet after release. We
immediately lengthened the incision in the fourth intercos-
tal space and performed open surgery to remove the device
and repair the ASD under CPB. Two patients (1 from each
group) were transferred to CPB surgery because of unstable
implanted ASD occlusions as verified by the push-pull ma-
neuver. In these 3 patients, ASD-CPB surgical repair was
successful and uneventful.
In total, 256 circular and 9 elliptical devices were used.
The mean size of all implanted circular devices was 30.4
 5.5 mm (range, 10–48 mm). The average size of circular
occluders in group A was 38.2  4.2 mm (range, 22–48
mm), larger than in group B (24.0  4.5 mm; range,
22–48 mm) (P < .001). Elliptical occluders were used
only in group A.
We listed the 2 typical patients with elliptical devices: In
1 female patient with an elliptical ASD 14332 mm, the rim
to aortic root, aortic valve, and right pulmonary vein was
0 mm, 3 mm, and 2 mm, respectively. We chose an
18336-mm elliptical device that successfully occluded
the ASD. In 1 female patient with an elliptical ASD
25315 mm, the rim to aortic root and aortic valve was
0 mm and 5 mm, respectively. We first placed a 30-mm cir-
cular occluder; however, atrioventricular conduction block-
ing occurred, so we redeployed a 16332-mm elliptical
occluder, and the atrioventricular conduction blocking
recovered automatically.
The average procedure time for all study patients was
37.2 9.2 minutes (range, 34–81 minutes). The average in-
tracardiac manipulation time was 5.8 3.0 minutes (range,
1–48 minutes), with no statistically significant difference
between groups.
Postoperative Results
All patients were transferred to the ICU for extubation
and postoperative recovery. The average mechanical
support time was 2.2  1.3 hours (range, 1.8–4.0 hours).
The average length of stay in the ICU and hospital was
6.3  4.2 hours (range, 4.0–11.2 hours) and 3.2  0.8
days (range, 2–7 days), respectively. No statistically signif-
icant difference existed between the 2 groups with respect
to these postoperative data (Table 4).
Follow-up
The total follow-up period ranged from 6 to 93 months
(median, 43 months). Follow-up results (physical examina-
tion and transthoracic echocardiograms) were available
for analysis in 260 patients at 1 month, 237 patients at
3 months, 195 patients at 1 year, 140 patients at 2 years,
92 patients at 4 years, and 69 patients at more than 6 years.
Table 5 lists the early (occurring within 30 days of opera-
tion) and late (occurring > 30 days postoperative)rdiovascular Surgery c Volume 142, Number 1 115
FIGURE 1. Schematic for the main steps of TTO. A, Under TEE guidance, the sheath is inserted through a right atrial puncture and ASD. B, The atrial disc
is extruded in the left atrial and adjusted to be parallel with the atrial septum. C, The sheath and cable are withdrawn until the occlusion disc joins the atrial
septum. D, Confirm via a repeated push-pull maneuver. E, The sheath is withdrawn if satisfactory ASD occlusion is achieved. F, The selected occlusion
device in a straight sheath. G–I, TEE guidance during the process of ASD occlusion. J, An approximate 2.0 incision left before discharge.
Congenital Heart Disease Wei et al
C
H
Dcomplications identified in the follow-up period. Small re-
sidual shunts (<2 mm) were found by TTE before discharge
in 3 patients with double-orifice ASDs. All these residual
shunts closed during follow-up (at 3, 9, and 16 months).
Congestive heart failure developed in 4 patients (3 in group
A) in the ICU, and they recovered by discharge. No heart
perforation or device embolization occurred in any patient
during the entire follow-up period. No statistically signifi-
cant difference in the occurrence of early or late complica-
tions was found between the 2 groups.DISCUSSION
The ASD is one of the most common congenital heart
diseases. TTO of ASD, different from traditional surgicalTABLE 2. Patient characteristics
All patients
No. of patients 268
Gender
Male/female 97/171
Mean age (y, SD, range) 15.9 (8.2), 2–65 15.
Mean BW (kg, SD, range) 36.5 (12.7), 12.5–81.8 38.
Morphology of ASD
Size (mm, SD, range) 26.9 (6.1), 5–44 33.
>30 mm 127 (47.4%) 8
Type
Central 187 (69.8%) 5
SVC 22 (8.2%) 1
IVC 39 (14.6%) 3
Blending 20 (7.5%) 2
Double orifice 15 (5.6%)
Aneurysm of IAS 15 (5.6%)
SD, Standard deviation; BW, body weight; ASD, atrial septal defect; SVC, superior vena c
116 The Journal of Thoracic and Cardiovascular Surgclosure and TCO methods, is a new ingenious hybrid
method for ASD closure. The present study reports the early
and mid-term results of TTO for ASD occlusion in 268
patients, of whom 126 were considered unsuitable for TCO.Safety and Efficacy of Transthoracic Occlusion
Currently, the mortality of anymethod for ASD closure is
close to zero.1 However, both CPB surgical closure and
TCO of ASD are associated with morbidity.8,13
Conventional surgery carries the consequence of operative
trauma, an unsightly scar, and CPB-related deleterious ef-
fects.14,15 Device embolization, residual shunt, vessel
injury, and perforation of the heart have been reported in
cases of TCO of ASD. Complication rates for CPBGroup A Group B P value
126 142
45/81 52/90 .878
4 (9.3), 2–65 16.3 (8.8), 2–2 .928
8 (14.5), 12.5–72.2 34.5 (11.6), 13.0–81.8 .837
6 (4.5), 12–44 21.0 (5.1), 5–38 <.001
9 (70.6%) 38 (26.8%) <.001
3 (42.1%) 134 (94.4%) <.001
7 (13.5%) 5 (3.5%) .003
6 (28.6%) 3 (2.1%) <.001
0 (15.9%) 0 (0%) <.001
9 (7.1%) 6 (4.2%) .300
7 (5.6%) 8 (5.6%) .978
ava; IVC, inferior vena cava; IAS, interatrial septum.
ery c July 2011
TABLE 3. Analysis of the reasons for transcatheter occlusion
unsuitability in the transthoracic occlusion group
Main reasons No. of patients
Age (<3 y) 8 (6.3%)
Size 35 (27.8%)
Diameter>36 mm 24
Relatively oversized* 11
Rim 72 (57.1%)
Superior-posterior rim (toward SVC) 4
Posterior rim (toward PV) 19
Inferior rim (toward AV) 35
Anterior-superior rim (toward AR) 14
IASy 7 (5.6%)
Peripheral vascular disease 3 (2.4%)
Allergic to radiography agent 1 (0.8%)
Total 126
SVC, Superior vena cava; PV, pulmonary vein; AV, aortic vein; AR, aortic root; IAS,
interatrial septum. *Oversized: ASD requiring an occluder with sheath size larger
than patient’s femoral vein diameter. yIAS too floppy/soft.
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Dsurgery and TCO have been reported as 24% and 7%,
respectively.2 Vida and colleagues16 reported early compli-
cation rates for surgery and TCO as 10.7% and 4.1%, re-
spectively, with a complete closure rate of 87.5% for both
modalities together. Majunke and colleagues17 reported 2
device embolizations and 6 patients requiring emergency
or elective surgery in 572 patients who underwent TCO.
In 2002, we reported the promising clinical results of the
earliest 33 patients undergoing TTO closure of ASD.10 Six
years later, Tao and colleagues11 reported updated results of
53 patients; only 1 patient had a minimal residual shunt that
resolved without complication. Hongxin and colleagues12
reported 1 patient with a moderate residual shunt during
follow-up. In the present study, there was zero mortality
in the 268 patients investigated. The complete closure rate
was 98.9%. No severe complications occurred during the
perioperative period or in the 8 years of postoperative
follow-up. No reoperation was necessary for any patient.
In addition to the data demonstrating a short averageTABLE 4. Postoperative results and inpatient statistics
All patients
Successful implantation 265/268
Rate of redeployment 17/268
Transferred to CS 3
Size of device
Circular diameter (mm, SD, range) 256 30.4 (5.5), 10–48
Elliptical 9
16–28 mm in radial
32–46 mm in longitudinal
Mean IMT (min, SD, range) 5.8 (3.0), 1–48
Mean TOT (min, SD, range) 37.2 (9.2), 34–81
Mean MST (h, SD, range) 2.2 (1.3), 1.8–4.0
Duration in ICU (h, SD, range) 6.3 (4.2), 4.0–11.2
Duration in hospital (d, SD, range) 3.2 (0.8), 2–7
CS, Conventional surgery; IMT, intracardiac manipulation time; TOT, total operative time
The Journal of Thoracic and Caprocedure and intracardiac manipulation time with TTO,
47% patients in our study were deemed unsuitable for
TCO treatment. No randomized comparisons of TCO ver-
sus TTO for ASD occlusion are currently available, but
our study’s results are strongly convincing as to the utility,
safety, and efficacy of TTO.Differences Between Inclusion Criteria of
Transthoracic Occlusion and Transcatheter
Occlusion
Patient selection is vital for prediction of successful
occlusion and repair of ASD. Generally, secundum ASDs
suitable for percutaneous closure should be 35 mm or less
(some authors suggest a maximal stretch diameter of
36–38 mm) in stretched balloon diameter, with a sufficient
(>5 mm) rim of surrounding atrial tissue.1,4,8
In the present study, TTO inclusion criteria were formu-
lated on the basis of our experience. Our TTO inclusion cri-
teria broadened the currently accepted general criteria for
TCO repair of ASD by decreasing rim length requirements
and eliminating anyASD size limitation. Themost common
cause of TCO exclusion is too short an ASD rim length, es-
pecially the inferior rim. Large ASD size is the second most
common reason for TCO exclusion, including an absolute
upper limit cutoff size greater than 36 mm and a relative
oversize (ASD requires an occluder with a sheath size larger
than a patient’s femoral vein diameter). The third most com-
mon reason for TCO exclusion is intra-atrial septal floppi-
ness or rim softness prohibitive for TCO repair (the cause
of previously failed TCO attempts in 3 patients). Infrequent
causes of TCO exclusion included peripheral vascular
disease and contrast agent allergy.Rationale for the Broader Transthoracic Occlusion
Inclusion Criteria Over Transcatheter Occlusion
The occluder delivery sheath is short, hard, and perpen-
dicular to the ASD. It is easier to guide the sheath acrossGroup A Group B P value
124/126 141/142 .493
11/126 6/142 .131
2 1 .132
115 38.2 (4.2), 22–48 141 24.0 (4.5), 10–42 <.001
9 0 .001
16–28 mm in radial
32–46 mm in longitudinal
6.8 (3.4), 2–48 5.0 (4.2), 1–35 .321
37.9 (10.9), 36–75 36.6 (8.7) 34–81 .912
2.3 (1.4), 1.9–3.9 2.1 (1.1), 1.8–4.0 .297
6.9 (4.1), 4.0–11.2 5.8 (3.7), 4.3–10.5 .554
3.1 (1.3), 2–7 3.3 (1.0), 2–6 .218
; MST, mechanical support time; ICU, intensive care unit; SD, standard deviation.
rdiovascular Surgery c Volume 142, Number 1 117
TABLE 5. Early* and late complications
All patients
(n ¼ 268)
Group A
(n ¼ 126)
Group B
(n ¼ 142)
P
value
Early complications (total) 18 10 8 .452
IAVB 3 2 1 .493
Residual shunt 3 2 1 .493
Atrial fibrillation 1 1 0 .288
Heart failure 4 3 1 .259
PPCS 3 1 2 .633
Pleural effusion 3 1 2 .633
Pericardial effusion 1 0 1 .345
Late complications (total) 7 4 3 .586
Atrial fibrillation 3 2 1 .493
PPCS 3 1 2 .633
Pleural effusion 1 1 0 .288
Total complications 25 14 11 .345
CS, Conventional surgery; TSVT, transient supraventricular tachycardia; IAVB, in-
complete atrioventricular block; PPCS, post-pericardiotomy syndrome. *Events oc-
curring within 30 d after occlusion were considered early.
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Dthe defects and adjust the device for proper anchoring. For
patients with a large ASD of short rim measurements, the
surgeon is able to push the sheath by hand against the short
rim and deploy the device into proper position. The surgeon
is also able to use a powerful push-pull maneuver through
the delivery cable to confirm device stability. However,
for TCO, the delivery sheath is long and soft, and there is
a 450-degree angle between the septum and the inferior
vena cava. When the entire system is withdrawn, the sheath
and device move inferiorly toward the inferior vena cava,
rather than in the ideal left to right direction. Kutty and col-
leagues18 and Nounou and colleagues19 tried to improve the
delivery system by changing the guide catheter or angle of
the attached occluder device, but it remains difficult to
achieve the ideal perpendicular approach and impossible
to perform the push-pull maneuver via TCO.
The shape and stiffness of the TTO occluder itself have
certain advantages over those used in TCO. To our knowl-
edge, the elliptical occluder used in our study is the first
and only reported device of its kind. The anatomic shape
of the ASD is more elliptical than it is round. If the longitu-
dinal diameter is not significantly larger than the radial di-
ameter of the ASD, a circular occluder can be used to
repair the ASD. However, if the longitudinal diameter is
much longer than the radial diameter (23), a round
occluder will encroach severely on tissues in the radial as-
pects; it is well known that the atrioventricular node and at-
tachment of the mitral valve regularly inhabit this region.
The transcatheter approach uses a long and soft delivery
sheath that cannot implant asymmetric occluders. Also,
the occluders used in the present study are harder than the
Amplazer’s septal occluder. Our results demonstrated that
the harder occluder did not increase the complication of ero-
sion, perhaps because most of the erosion occurred as the
result of instability of the implanted device. The relative118 The Journal of Thoracic and Cardiovascular Surgmovement between the device and the surrounding struc-
tures can cause the chronic damage and erosion. The in-
creased stiffness could help the 2 edges of the device
clamp the rim of ASD more tightly.20
TEE plays an important role in TTO. TEE can provide
real-time Doppler feedback of the existing ASD shunt,
help guide adjustment of the occluder’s position, and con-
firm a successfully closed ASD during repeated push-pull
maneuvers. In addition, TEE can evaluate the hardness of
the rims surrounding the ASD by the strength of echo reflec-
tion; certain soft rims will require a larger occluder
device.20
TTO extends inclusion criteria to the pediatric popula-
tion. In young children, the femoral vessel diameter is
proportionally small compared with ASD size. Even with
considerations of femoral vascularelasticity,21,22 if the
ASD is large, the vessel is apt to be injured. However, the
intercostal space is large enough to transfer the delivery
sheath in children at least 2 years old. Therefore, the TTO
method provides a manner of ASD closure to a greater
pediatric population with larger ASD dimensions.
TTO procedures are performed in cardiac surgery opera-
tion rooms, where CPB is readily available. Patients are
endotracheally intubated under general anesthesia. In the
event of a failed occlusion, device embolization, hemor-
rhage, or malignant arrhythmia, the patient would be
directly converted to CPB surgery. This safety net broad-
ened the potential to attempt TTO in even difficult ASD
cases.
According to the results of the present study, TTO is safe
and efficacious with the advantages discussed. In addition,
because TTO is relatively easy to learn, there is a swifter
learning curve for the technique. TTO does not require fluo-
roscopy, eliminating the potential for radiation injury or se-
quelae. Perhaps the most outstanding aspect of TTO of ASD
is its practical utility in patients deemed unsuitable for TCO
management. Our follow-up results demonstrate that ap-
proximately 5.5% of patients could avoid CPB operation
by undergoing TTO. On the basis of the high morbidity of
ASD, many patients are in this category, and we believe
TTO, with its unique advantages, will have increased im-
portance and application in the future of ASD treatment.
Study Limitations
This was a retrospective study and is limited because it
was not a randomized, controlled double-blinded study. It
is difficult to perform a randomized and double-blinded
study for ASD closure for obvious ethical and logistic
reasons. Both TCO and conventional CPB surgeries were
performed during the study period, but the present study
did not compare TTO with TCO or conventional surgery.
The different inclusion criteria for patients suitable for
TTO, TCO, and conventional surgical repair of ASD
make a comparison analysis of patient outcomes difficult.ery c July 2011
Wei et al Congenital Heart DiseaseThe present study compared the results of 2 patient groups
deemed fit or unfit for TCO ASD repair, and the follow-up
results from both 2 groups are equally outstanding.
CONCLUSIONS
TTO, a novel method of ASD treatment pioneered by the
Institute of Cardiovascular Surgery, is safe and relatively
easy to perform, and carries low morbidity. Most important,
TTO has a role in successfully treating ASD lesions that are
unsuitable for the TCO method. With its record of safety
and efficacy, TTO is currently being performed in many in-
stitutions in China and will likely be applied more widely
for ASD treatment in the future.
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